Heterogeneous nuclear ribonucleoproteins (hnRNPs) represent a large family of RNA-binding proteins. Heterogeneous nuclear ribonucleoprotein D-like (HNRPDL) is a member of this family. Though aberrant expression of HNRPDL has been reported in a few cancers, whether HNRPDL is deregulated in colon cancer patients and what role this protein plays in these cells are not known yet. In this study, we found that HNRPDL was significantly up-regulated in colon cancer specimens than control. We also demonstrated that HNRPDL silencing inhibited the growth of SW620 cells both in vitro and in vivo. Conversely, we constructed a retroviral vector to deliver HNRPDL into non-malignant NIH-3T3 cells and injected these cells into nude mice. HNRPDL-overexpressing NIH-3T3 cells generated tumors in nude mice but not the control cells. Mechanistically, HNRPDL promoted cell-cycle progression associated with enhanced expressions of cyclin D3 and Ki-67 but decreased expressions of p53 and p21. Taken together, our data demonstrate that HNRPDL is aberrantly expressed in colon cancer cells, which promotes the growth of these cells by activating cell-cycle progression.
Introduction
Heterogeneous nuclear ribonucleoprotein D-like (HNRPDL) is a DNA/RNA-binding protein containing two RNA-binding domains (RBDs), KH domain and a glycine-rich domain at C-terminus, which belongs to heterogeneous nuclear ribonucleoproteins (hnRNPs) [1] . HNRPDL is expressed in most tissues of mice [2] . It resides in both nucleus and cytoplasm and the C-terminus is responsible for the shuttling between nucleus and cytoplasm [3, 4] . HNRPDL has two transcript variants generating two protein products with the molecular weight of 53 kDa and 38 kDa, respectively [2] . HNRPDL was cloned by two independent groups almost at the same time [5, 6] . HNRPDL modulates the gene expression through its interaction with other transcriptional factors [7] . HNRPDL also binds to single-stranded C-rich telomeric motif with limited specificity, suggesting that it possibly plays a role in the maintenance of genome stability [8] . HNRPDL is also able to bind with poly(A)
+

RNAs rather than poly(A)
− RNAs in a sequence-specific manner [9] .
Previous studies have shown that HNRPDL increases the internal translation initiation and maintains the stability of mRNA through binding with 5′-and 3′-untranslated region (UTR) of mRNA, respectively [10, 11] . Accumulating data have shown that HNRPDL has multiple functions and is implicated in various human diseases, such as limb-girdle muscular dystrophy 1 G (LGMD1G), neurodegenerative disorders and cancers [12] [13] [14] [15] [16] [17] [18] . Two independent genetic profiling studies have identified that HNRPDL is up-regulated in hepatocellular carcinoma rather than in non-tumor liver tissue [14, 15] . de Wit et al. [16] suggested that HNRPDL was one of the candidate colorectal cancer biomarkers with secretome proteome approach. Wu et al. [17] showed that HNRPDL (also known as JKTBP) expression was significantly increased in androgen-independent (AI) prostate cancer tissues compared with the androgen-dependent (AD) prostate cancer tissues. The ectopic HNRPDL expression was found to lead to androgen-independent growth of LNCaP cells associated with increased expressions of EGF-R and prostate-specific antigen (PSA) but not androgen receptor [17] . Our previous data showed that HNRPDL was significantly up-regulated in CD34
+ cells from chronic myeloid leukemia (CML) patients compared with those from healthy donors, and the silence of HNRPDL suppressed the in vitro growth of K562 cells [18] . Moreover, several studies suggested that HNRPDL played a role in drug response of cancer cells [19] [20] [21] . For example, quercetin suppressed the growth of colon cancer Caco-2 cells and microarray analysis revealed that HNRPDL expression was significantly decreased upon quercetin treatment [19] . However, what roles HNRPDL plays in colon cancer cells has not been elucidated yet.
In the present study, the expression of HNRPDL in malignant tissues was determined and compared with the non-malignant control, and the role of HNRPDL in the growth of SW620 cells was explored in vitro and in vivo. We also constructed a retroviral vector to deliver HNRPDL into non-malignant NIH-3T3 cells and investigated its effects on cell growth, colony-forming ability and migration. In addition, we analyzed the cell-cycle alteration upon HNRPDL manipulation in both SW620 and NIH-3T3 cells. As far as we know, these data have demonstrated for the first time that HNRPDL is aberrantly expressed in colon cancer patients and that HNRPDL is required for the growth of these cells through its transformation ability by promoting cell-cycle progression.
Materials and Methods
Ethics statement
The specimens from human colorectal cancer patients and nonmalignant patients were collected from the Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine with written informed consent approved by the Ethical Committee of Nanjing University of Chinese Medicine. The clinical characteristics of colorectal cancer patients were summarized in Supplementary Table S1 . The animal studies were approved by the Animal Experimental Committee of Soochow University and performed in accordance with the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals.
Immunohistochemical analysis of human samples
To evaluate the expression of HNRPDL in colorectal cancer tissues, the specimens of malignant tissues from 10 individual patients (four male and six female) and four non-malignant tissues were stained with immunohistochemistry method using a commercial kit (GTVision TM III; Gene Tech, Shanghai, China). A brief description of the procedure recommended by the manufacturer was as follows. The paraffin embedded sections were transferred onto glass slides.
To remove the paraffin, the slides were treated with dimethylbenzene for three times and then they were treated with a serial concentration of ethanol (100%, 95%, 85% and 70%, each for 5 min) and 1 × PBS (three times). To block the endogenous peroxidase, the slides were immersed into 3% solution of hydrogen peroxide and then washed with 1 × PBS. The slides were treated with blocking buffer at room temperature and then incubated with anti-HNRPDL antibody (1:150; Abcam, Cambridge, USA) at 4°C overnight. The slides were treated with A solution from the kit for 30 min at room temperature. Freshly prepared DAB solution was used to incubate the slides at room temperature to develop, and the reaction was stopped by rinsing with deionized water. The slides were stained with haematoxylin and then dehydrated with a serial concentration of ethanol (85%, 95% and 100%, each for 5 min). Finally, the slides were observed under a microscope and images were captured with a digital camera. An adjacent section of each specimen was also analyzed with hematoxylin-eosin (H&E) staining for histophathological evaluation. The quantification of immunohistochemistry data was performed with Image-Pro Plus 6.0 software.
Cells and culture media
NIH-3T3, 293 T and SW620 cells were purchased from the Cell Bank of Shanghai Institutes for Biological Sciences of the Chinese Academy of Sciences (Shanghai, China). Both NIH-3T3 and 293 T cells were maintained in DMEM (Thermo Fisher Scientific, Waltham, USA) supplemented with 10% fetal bovine serum (FBS); while SW620 cells was maintained in Leibovitz's L-15 Medium (Thermo Fisher Scientific) supplemented with 10% FBS.
Retroviral and lentiviral production
A retroviral vector (pMSCV-IRES-YFP, pMIY) was originated from Dr Keith Humphries (Terry Fox Laboratory, British Columbia Cancer Research Center, Vancouver, Canada). The packaging plasmid (pCGP) to produce retrovirus was a gift from Dr Hudan Liu (Wuhan University, Wuhan, China). HNRPDL cDNA (longer form) was purchased from Origene (Rockville, USA). It was subcloned into the pMIY and the vector was verified by DNA sequencing. Lentiviral vectors to silence HNRPDL together with the scramble control were from GenePharma Co, Ltd (Shanghai, China). The sequences to silence HNRPDL were shRNA#1, 5′-GCACAACCCAAAGAGGTAT-3′ and shRNA#2, 5′-GGAACTGAAAGAACACAAACT-3′. The scramble sequence was 5′-TTCTCCGAACGTGTCACGT-3′. The lentiviral production was performed as previously described [18] .
Cell viability assay
The cell viability was assessed using a Cell Counting Kit-8 (CCK-8; Beyotime, Shanghai, China) following manufacturer's instruction. About 5000 cells were plated into 96-well plate with 100 μl media for culture. Before assessment, 10 μl CCK-8 reagents were added into each well and the cells were incubated at 37°C for another 4 h. The absorbance at two wavelengths (450 nm for the viable cells and 650 nm for the soluble dye) was measured with a microplate reader (SpectraMax M5; Molecular Devices, Sunnyvale, USA).
Soft agar colony formation assay
The soft agar assay was performed according to the previous description [22] . Briefly, 800 infected cells were added to culture media with 0.4% agar and layered onto 0.6% agar beds in 35 mm dishes. Cells were fed with 1 ml of culture medium every 3 days. Fourteen days later, the colonies were stained with 0.005% crystal violet and numerated.
Wound healing assay
The control and experimental cells were seeded in 6-well plates until formation of single-layer confluence. The cells were scratched with a sterile 200-μl pipette tip, and then images of cells in each well were captured under a microscope (Leica, Buffalo Grove, USA) at 0 h and 36 h time intervals post-scratching. The relative migration was estimated by comparing the distance of wound closure of experimental cells to that of control cells. The experiments were performed with three independent biological replicates.
RNA extraction and qRT-PCR analysis
Total RNA was extracted using PicoPure TM RNA extraction kit (Arturus, Mountainview, USA) and reverse transcribed with SuperScript III (Life Technologies, Grand Island, USA). qRT-PCR was performed using SYBR Green PCR MasterMix (Applied Biosystems, Foster City, USA) with 7500 real time PCR system (Applied Biosystems). The primers were as follows: β-ACTIN forward: 5′-CACCATTGGCAATGAGCGGTTCC-3′, reverse: 5′-TAG TTTCGTGGATGCCACAGG-3′; and HNRPDL forward: 5′-AG AATCAGCAGGATGACGGTA-3′, reverse: 5′-ACTTCCCCAAATC GAGACAAGT-3′.
Cell-cycle analysis
) were collected and washed with PBS thoroughly and then suspended in the remaining PBS. The cells were fixed with 70% pre-chilled ethanol and stored in freezer overnight. The cells were treated with RNase A at 37°C for 30 min, and then stained with propidium iodide (Sigma, St Louis, USA) at room temperature in the dark for 15 min. The cells were washed and resuspended in PBS for flow cytometry analysis (Calibur TM ; Becton Dickinson, Franklin Lakes, USA). The cell-cycle status was re-analyzed with FlowJo software (Ashland, USA).
Western blot analysis
Cell lysate was prepared using the protein lysis buffer (Beyotime) supplemented with 1 mM PMSF (final concentration), and then the protein samples with same amount ( 
Xenoengraftments with nude mice
Female nude mice (6-to 8-week-old) were purchased from Shanghai Laboratory Animal Center, the Chinese Academy of Sciences (Shanghai, China). Viral vector infected cells were purified by their fluorescent label (GFP or YFP) with a cell sorter and then injected subcutaneously into right flank of mice. The growth of the tumors was observed closely and tumor volume was estimated as: tumor volume = 1/2 × length × width 2 . Immediately after the mice were sacrificed, the fluorescent signal of tumor was detected by an IVIS Lumina II CCD camera system (Caliper Life Sciences, Hopkinton, USA) and then dissected for immunohistochemistry (IHC) and H&E analyses, respectively.
Statistical analysis
Data were presented as the mean ± SD from more than three independent experiments, and the statistical analysis was performed with Student's t-test, in which a P value <0.05 was considered significantly different.
Results
HNRPDL is aberrantly expressed in specimens from colorectal cancer patients
Although HNRPDL is deregulated in a few cancers including a report indicating that HNRPDL is a candidate biomarker for colorectal cancer [17] , there is no direct assessment of the expression of HNRPDL in specimens from colorectal cancer patients compared with normal tissues yet. In this study, we collected 10 specimens from colorectal cancer patients and non-malignant tissues to perform immunohistochemistry and H&E analyses. Representative images from patient #9 were shown in Fig. 1A . Quantitative analysis showed that carcinoma tissues had significantly stronger expression of HNRPDL than the non-malignant tissues (Fig. 1B) . In addition, two specimens had para-carcinoma regions, which allowed us to compare HNRPDL expression between carcinoma and paracarcinoma regions. The result showed that carcinoma region had significantly higher HNRPDL expression than para-carcinoma region (Patient #6; Supplementary Fig. S1 ). Taken together, our data demonstrated that HNRPDL was aberrantly expressed in colon cancer cells.
HNRPDL sustains the growth of SW620 cells in vitro and in vivo SW620 cells were used as a research model because they have strong tumorigenic ability to allow both in vitro and in vivo studies. Two independent shRNA sequences were designed and delivered into SW620 cells with lentiviral vectors. Compared with scramble sequence-transduced cells, the transcript expressions of HNRPDL in shRNA sequence-transduced cells were as low as 27% and 15%, respectively. Accordingly, the protein expressions of HNRPDL in shRNA-transduced cells were evidently decreased ( Fig. 2A) . HNRPDL silencing significantly inhibited the proliferation and colony-forming capacities of SW620 cells (Fig. 2B,C) . In addition, HNRPDL silencing significantly impaired the migration ability of these cells (Fig. 2D) . Since these two shRNA sequences had similar effects on the in vitro growth of SW620 cells, only shRNA#2 was used in the subsequent studies. The control and HNRPDL-silenced cells were subcutaneously injected into the right flank of nude mice, and the growth of tumors was monitored within 20 days post injection. HNRPDL silencing inhibited the growth rate of tumors (Fig. 3A) and reduced the tumor formation frequency of SW620 cells (8/8 vs. 5/8) as well (Fig. 3B) .
HNRPDL transforms NIH-3T3 cells
Although it is known that HNRPDL is aberrantly expressed in a few cancers and its down-regulation is implicated in the treatment of cancer cells with chemotherapies [14] [15] [16] [17] [18] [19] [20] [21] , whether HNRPDL is able to transform non-malignant cells has not been elucidated. In this study, we constructed a retroviral vector to overexpress the longer form of HNRPDL. The transcript and protein expressions of HNRPDL in NIH-3T3 cells were increased compared with control cells (Supplementary Fig. S2 ). The higher expression of HNRPDL significantly promoted the proliferation of NIH-3T3 cells and enhanced their colony-forming capacities (Fig. 4A,B) . The higher expression of HNRPDL sustained the proliferation of NIH-3T3 cells in the treatment of serum starvation (2% FBS) as well ( Supplementary Fig. S3 ). In addition, the higher expression of HNRPDL significantly promoted the migration ability of NIH-3T3 cells (Fig. 4C) . Strikingly, the higher expression of HNRPDL enabled NIH-3T3 cells to form tumors when the cells were subcutaneously injected into nude mice, while the control cells did not (Fig. 5) .
HNRPDL activates cell-cycle progression
To gain insights of how HNRPDL promotes the growth of NIH-3T3 cells and sustains the growth of SW620 cells in vitro and in vivo, we analyzed the cell-cycle status upon HNRPDL overexpression or HNRPDL silencing. When comparing the control cells with the HNRPDL-overexpressing NIH-3T3 cells, we found more G2/M fraction and less G0/G1 fraction in the HNRPDLoverexpressing cells (Fig. 6A, and Supplementary Fig. S4 ). Conversely, less G2/M fraction and more G0/G1 fraction were found in the HNRPDL-silenced SW620 cells (Fig. 6B , and Supplementary Fig. S4 ). Although HNRPDL silencing inhibited the growth of SW620 cells and led to cell-cycle arrest, this action did not trigger apoptosis ( Supplementary Fig. S5 ). Next, we performed western blot analysis to measure the expressions of cell cycle-related /mouse) were subcutaneously injected into the right flank of nude mice. Tumor volumes of both groups were compared every other day through Day 7 till Day 21 post injection. The average volumes of observed tumors were plotted. Tumors were observed in the injected site and one mouse had only one tumor. On Day 7 and Day 9, two and three mice in shRNA#2 group had tumor; in the subsequent days, five mice in this group had tumor. Over all the days, eight mice in the scramble group had tumor. (B) Twenty-one days post injection, photos of mice bearing tumors were taken, and the fluorescence was monitored with IVIS II imaging system. A representative photo was shown. Data were shown as the mean ± SD. *P < 0.05, **P < 0.01 and ***P < 0.001. proteins. Our data showed that cyclin A2, cyclin B1, cyclin D1, cyclin D2 and cyclin E1 were not altered upon HNRPDL manipulation consistently ( Supplementary Fig. S6 ). Interestingly, cyclin D3, Ki-67, p53 and p21 showed a consistent alteration upon HNRPDL manipulation (Fig. 6C, and Supplementary Fig. S7 ).
Discussion
Previous data have indicated the deregulation of HNRPDL in a few human cancers [14] [15] [16] [17] [18] . The deregulation of HNRPDL in colon cancer has been suggested by proteomic data [17] ; however it has not been validated yet. In the present study, we performed immunohistochemistry analyses of multiple malignant tissues together with control tissue. Our data clearly showed that HNRPDL is significantly up-regulated in colon cancers, suggesting that it might play a critical role in this disease. Currently, it is difficult for us to conclude that the aberrant expression of HNRPDL is associated with the sex of patients. Interestingly, the expression of HNRPDL in these specimens seems to be associated with the differentiation stage. The poorly differentiated specimens might have higher expression of HNRPDL (Supplementary Table S2 ). However, no clear conclusion can be made due to the limited number of specimens used in the current study. Next, we performed gene silencing experiment to delineate the function of HNRPDL in colon cancer using SW620 cells as model. Our data showed that HNRPDL silencing strongly inhibited the in vitro and in vivo growth of SW620 cells.
HNRPDL is implicated in various human diseases including cancers. However, whether this protein ultimately has the capacity of malignant transformation is not known yet. In this study, we injected HNRPDL-overexpressing NIH-3T3 cells into nude mice and found that these cells were able to form tumors in vivo, indicating that HNRPDL is an oncoprotein. In addition, HNRPDL enhances the growth, colony-forming capacity and migration of NIH-3T3 cells in vitro.
HNRPDL has two transcript variants resulting in two protein products [2] . In this study, the longer form of HNRPDL is able to transform NIH-3T3 cells. Conversely, the silence of HNRPDL (both longer form and shorter form, Fig. 3A ) inhibits the growth of SW620 cells. Based on these data, we speculate that the shorter form of HNRPDL is unlikely to have an opposite function to the longer form of HNRPDL. However, whether these two forms have similar or identical function still needs further investigation.
The understanding of the mechanisms of HNRPDL in cancer cell is limited. Wu et al. [16] have shown that overexpression of HNRPDL (longer form) activates epidermal growth factor-receptor (EGF-R) signaling, thus promoting androgen-independent growth of LNCaP cells [16] . In the present study, we showed that HNRPDL is able to regulate the cell-cycle status of both NIH-3T3 and SW620 cells. Several cell cycle-related proteins are regulated by HNRPDL, including cyclin D3, Ki-67, p53 and p21. Among these factors, p53 is not only a cell-cycle regulator but also has multiple functions. Despite the inability to induce apoptosis by HNRPDL silencing, it is reasonable to speculate that HNRPDL-silenced cells may have increased sensitivity to chemotherapy due to enhanced p53 expression. In addition, the inhibition of p53 by ectopic expression of HNRPDL in NIN-3T3 cells may be an important clue for us to understand the transforming ability of HNRPDL. However, more detailed studies are needed to delineate the molecular mechanisms of how HNRPDL promotes cellular growth, as this protein is able to regulate gene expression transcriptionally and post-transcriptionally.
Taken together, we have demonstrated that HNRPDL is aberrantly expressed in colon cancer cells, which conferring these cells growth advantage through its ability to promote cell-cycle progression.
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